FDAnews Drug Daily Bulletin

APHTON ANNOUNCES CLOSING OF COMMERCIALIZATION AND MANUFACTURING AGREEMENTS FOR IGN311 WITH CELLTRION

Nov. 18, 2005
A A

Aphton Corporation (NASDAQ:APHT) announced the formal completion of two agreements with Celltrion, Inc., South Korea for the licensing and commercialization and the product development and manufacturing of Aphton's clinical product candidate IGN311. IGN311, a humanized monoclonal antibody targeting the Lewis Y antigen, is being developed by Aphton's wholly-owned subsidiary, Igeneon AG, as a potential new therapy for the treatment of cancer. Lewis Y is a tumor-related antigen that is expressed in up to 90% of all epithelial cancers, including breast, colon, gastric, and pancreatic cancers.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051117005428&newsLang=en)